TY - JOUR
T1 - Effects of β-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection
AU - Romney, Seymour L.
AU - Ho, Gloria Yuen Fun
AU - Palan, Prabhudas R.
AU - Basu, Jayasri
AU - Kadish, Anna S.
AU - Klein, Sara
AU - Mikhail, Magdy
AU - Hagan, Robert J.
AU - Chang, Chee Jen
AU - Burk, Robert D.
PY - 1997/6
Y1 - 1997/6
N2 - Women with histopathologically confirmed cervical intraepithelial neoplasia (CIN) were followed at 3-month intervals in a randomized double- blinded trial to evaluate the efficacy of β-carotene to cause regression of CIN. Questionnaire data, plasma levels of micronutrients, and a cervicovaginal lavage for human papillomavirus (HPV) detection were obtained at each visit, and an endpoint biopsy was performed at 9 months. Sixty-nine subjects had a biopsy endpoint evaluation; 9 of 39 (23%) subjects in the β- carotene group versus 14 of 30 (47%) in the placebo group had regression of CIN (P = 0.039). Independent risk factors for persistent CIN at 9 months included type-specific persistent HPV infection (OR = 11.38, P = 0.006) and continual HPV infection with a high viral load (OR = 14.25, P = 0.007) at baseline and 9 months, an initial diagnosis of ≤CIN II (OR = 6.74, P = 0.016), and older age (OR for ≤25 years = 4.10, P = 0.072). After controlling for these factors, the β-carotene and placebo groups did not differ in risk for having CIN at 9 months (OR = 1.53, P = 0.550). Resolution of baseline HPV infection was significantly correlated with non-high-risk HPV types (RR = 2.94, P = 0.015), age <25 years (RR = 2.62, P = 0.014), and douching after sexual intercourse (RR = 3.02, P = 0.012), but not with randomization group. Our data indicate that a large proportion of mild CIN lesions regress; age and HPV infection play an important role in the natural course of CIN; and repeated HPV testing may have a value in distinguishing women who need aggressive treatment for CIN versus those who do not. Supplementation of β-carotene does not appear to have a detectable benefit in treatment of CIN.
AB - Women with histopathologically confirmed cervical intraepithelial neoplasia (CIN) were followed at 3-month intervals in a randomized double- blinded trial to evaluate the efficacy of β-carotene to cause regression of CIN. Questionnaire data, plasma levels of micronutrients, and a cervicovaginal lavage for human papillomavirus (HPV) detection were obtained at each visit, and an endpoint biopsy was performed at 9 months. Sixty-nine subjects had a biopsy endpoint evaluation; 9 of 39 (23%) subjects in the β- carotene group versus 14 of 30 (47%) in the placebo group had regression of CIN (P = 0.039). Independent risk factors for persistent CIN at 9 months included type-specific persistent HPV infection (OR = 11.38, P = 0.006) and continual HPV infection with a high viral load (OR = 14.25, P = 0.007) at baseline and 9 months, an initial diagnosis of ≤CIN II (OR = 6.74, P = 0.016), and older age (OR for ≤25 years = 4.10, P = 0.072). After controlling for these factors, the β-carotene and placebo groups did not differ in risk for having CIN at 9 months (OR = 1.53, P = 0.550). Resolution of baseline HPV infection was significantly correlated with non-high-risk HPV types (RR = 2.94, P = 0.015), age <25 years (RR = 2.62, P = 0.014), and douching after sexual intercourse (RR = 3.02, P = 0.012), but not with randomization group. Our data indicate that a large proportion of mild CIN lesions regress; age and HPV infection play an important role in the natural course of CIN; and repeated HPV testing may have a value in distinguishing women who need aggressive treatment for CIN versus those who do not. Supplementation of β-carotene does not appear to have a detectable benefit in treatment of CIN.
UR - http://www.scopus.com/inward/record.url?scp=0031172861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031172861&partnerID=8YFLogxK
U2 - 10.1006/gyno.1997.4697
DO - 10.1006/gyno.1997.4697
M3 - Article
C2 - 9190980
AN - SCOPUS:0031172861
SN - 0090-8258
VL - 65
SP - 483
EP - 492
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -